Ascending dose‐controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women

Overview of attention for article published in Obesity, May 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

blogs: 2 blogs
twitter: 5 X users
patent: 19 patents

facebook: 1 Facebook page
wikipedia: 1 Wikipedia page

Citations

dimensions_citation: 58 Dimensions

Readers on

mendeley: 103 Mendeley

Summary Blogs X Patents Facebook Wikipedia Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 21,418 followers.

@KSSMDPhD $ZFGN have to disagree with you there. See previous Beloranib (hate that word) phase 1 https://t.co/qMMqLqzpoT Beloranib truly was a beast!

Reply Repost Favourite

@bio_clouseau @adamfeuerstein @JohnCendpts https://t.co/VMWZJIWq0X and https://t.co/zX5XQsHoAU

Reply Repost Favourite

http://t.co/AWSAs7jSQ2

Reply Repost Favourite

New injectable weight loss drug Beloranib, a fumagillin-class methionine aminopetidase-2 (MetAP2) inhibitor, sheds... http://t.co/2aCOORWvC6

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.